Some biotech stocks are built around one big make-or-break gamble. Halozyme is playing a different game. Instead of betting the farm on a single headline drug, it has built a business around helping other companies improve how their treatments get delivered.
That may sound less exciting on the surface, but it can also be a much steadier way to make money. And lately, the setup has been getting harder to ignore as new deals stack up and guidance keeps moving higher.
Critical Metal Squeeze (Sponsored)
Operation Epic Fury hit over 2,000 targets in just 96 hours — and exposed a critical dependency: titanium.
Every stealth bomber, missile, and drone relies on it. Yet the U.S. imports 95% of its supply, while China dominates global production.
Project Blue warns a supply crunch is coming — aerospace and defense first.
A new North American discovery shows promise:
31 drill holes, all consistent
Magnetic readings maxed out
Potential to rival China’s largest deposits
With infrastructure ready and a maiden resource estimate expected in 2026, this could reshape the supply chain.
Get the full breakdown
What Just Happened
Halozyme Therapeutics has been getting fresh attention after lifting its financial outlook and landing more licensing wins tied to its ENHANZE drug delivery platform. Benchmark reiterated its Buy rating and $75 price target after the company raised guidance for 2025 and 2026, helped by stronger royalty revenue and new agreements signed near year-end.
Those included deals with Takeda, Merus, and Skye, all tied to Halozyme’s core technology. At the same time, not everyone is sold. Goldman Sachs maintained a Sell rating with a $58 price target, which tells you this is still a stock with a debate around it rather than one the whole Street has already crowned.
The bigger point is not just that Halozyme had a nice update. It is that the company laid out a much longer runway than many investors probably expected. Revenue guidance for 2026 came in at $1.71 billion to $1.81 billion, followed by another step higher in 2027 and 2028. That kind of multi-year visibility tends to matter a lot more than one strong quarter, especially in biotech where investors are used to wild swings and fragile narratives.
The Business People Underestimate
Halozyme is easy to misread if you only glance at the headline description. This is not your typical biotech story built around one internal drug candidate that either becomes a blockbuster or ends up in the graveyard.
The real engine here is ENHANZE, a drug delivery technology that can help pharma companies create subcutaneous versions of certain therapies.
That matters because convenience matters.
If a treatment can be delivered more easily or more quickly, that can make it more appealing for patients, doctors, and healthcare systems. It can also help a drugmaker extend the usefulness and competitiveness of an existing therapy. Halozyme’s role is to provide the platform that helps make that happen.
In exchange, it can collect upfront payments, milestone payments, and royalty revenue.
That is what makes the business so interesting. Halozyme does not need to discover every blockbuster drug itself. It just needs other companies with valuable drugs to keep seeing value in a better delivery format.
That creates a pretty attractive position in the chain. It is not carrying every ounce of development risk, but it still gets a slice of the upside when partners succeed.
Trivia: What does the first digit of a credit card number indicate?
Smart Briefing (Sponsored)
Every day before 6AM, Matthew Tuttle sits down at his trading desk in Connecticut to write to you about hedges, edges, asymmetric opportunities and themes in the market.
Get his free Daily H.E.A.T. email for a dose of actionable market insight every weekday morning.
Why The Story Has Been Working
There are three main reasons this stock has been gaining traction.
First, the deal flow is still alive. The new agreements with Takeda, Merus, and Skye show that ENHANZE is still attracting fresh interest from drug developers. That is important because it supports the idea that Halozyme is not just riding a few legacy wins. The platform is still expanding its reach.
Second, the royalty stream is getting more attention. This is the part of the model that investors usually love most because royalties can scale very nicely. Benchmark specifically highlighted stronger royalty revenue as a key reason behind the improved outlook.
When royalty revenue starts doing more of the heavy lifting, the business can begin to look less like a science project and more like a durable cash generator.
Third, management is giving the market a reason to think the momentum is not a one-season wonder. Raised guidance for 2025 is good. A strong forecast for 2026, 2027, and 2028 is even better. Investors are far more willing to pay up for a stock when they believe the runway extends well beyond the next earnings call.
Want to make sure you never miss a stock recommendation?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell. Email’s great. Texts are faster.
Why The Stock Could Still Work
The easy money may already be gone, but the story still has room if execution holds.
One reason is that Halozyme has a much cleaner business model than many biotech names. It is not living and dying by one binary event. It has multiple partners, multiple agreements, and several ways to earn revenue. That does not eliminate risk, but it does make the setup less fragile than a lot of biotech stories that can collapse on one bad update.
Another reason is that analyst estimates have been trending in the right direction. Zacks flagged the stock as a new buy partly because earnings expectations have been moving higher. That matters because rising estimates often help fuel buying interest, especially among investors looking for names with improving fundamentals rather than just good headlines.
There is also a very practical retail-investor angle here. Halozyme is participating in the success of other companies’ drugs without having to spend all of its energy trying to become a giant full-service pharma company.
That may not sound glamorous, but it can be a very profitable place to sit if more partners keep signing on and more products keep generating royalties.
Wealth Shift Accelerating (Sponsored)
Hedge fund legend Larry Benedict, who went 20 consecutive years without a single losing year…
Predicts Trump's "Project 2026" is about to move hundreds of billions of dollars into ONE ticker.
And it's not a chip stock. Not a resource stock. Not Tesla or NVIDIA.
It's something completely different… something that's been overlooked for years.
Click here to get the details because Larry helped his readers make 279% in 2025 on a return-on-cash basis… and he says this could be even bigger.
What Could Go Wrong
Of course, this is still biotech, so the risks are real.
The first one is partner dependence. Halozyme may not carry all the risk of developing every drug itself, but it still depends on partners to keep programs moving, win approvals, execute commercially, and maintain demand. If a major partner runs into trouble, Halozyme can feel the pain too.
The second risk is expectations. Once a company starts raising guidance and laying out a big long-term runway, the market can get spoiled. At that point, even a decent quarter might not be enough if investors were hoping for fireworks.
The third risk is deal quality over time. Halozyme has a valuable niche, but pharma companies are tough negotiators. Future agreements may not always be as attractive as investors hope, and competition or bargaining pressure could affect the economics of new deals.
And finally, the stock is not universally loved. The spread between bullish and bearish analyst targets is a reminder that there is still real disagreement over how much upside is left from here.
What I’d Watch Next
For the next few quarters, the checklist is pretty simple.
Watch for new ENHANZE deals. Watch whether royalty revenue keeps climbing. Watch whether management continues to support or raise the long-term outlook. And watch whether earnings estimates keep drifting higher.
If those boxes keep getting checked, the bull case stays intact.
My Take
Halozyme has a very funny problem for a winning stock. It sounds less exciting than it actually is.
A lot of investors hear drug delivery platform and immediately start looking for something flashier. But Halozyme has built a business that may let it profit when other companies’ drugs win, and that can be a very comfortable seat in biotech. It is not risk-free, and the stock is not some undiscovered bargain anymore. But it does look like a more durable setup than many of the louder names in the space.
The clean bull case is simple. More partners sign on. Royalty revenue grows. Guidance holds up. And investors keep warming to a business model that gets paid without having to do all the heaviest lifting itself.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
